Tamer Yacoub, MD
Endocrinology, Diabetes & Metabolism · Fall River, MANPI 1578557807
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $612,843 of the $775,288 with a category attached, or 79.0%. 57 manufacturers reported payments, led by Novo Nordisk at 32.1% of the total. Among endocrinology, diabetes & metabolism clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,539 payments — averaging $503.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$249K
- Lilly USA, LLC$214K
- Corcept Therapeutics$53K
- Bayer$37K
- Abbott$33K
- Ascendis Pharma Endocrinology Inc$32K
- plus $157K from 51 others
Across 64 payments — averaging $10,871 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$631K
- AbbVie$24K
- Corcept Therapeutics$22K
- F. Hoffmann-la Roche AG$11K
- Genentech, Inc.$5K
- Bayer$2K
- plus $955 from 1 others
What the payments were for
- Consulting fees$48,4556%
- Speaking & faculty fees$612,84379%
- Travel & lodging$78,93210%
- Food & beverage$34,6534%
- Education$3460%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MOUNJARO$86,742
- ZEPBOUND$74,060
- Saxenda$73,003
- Ozempic$66,664
- JARDIANCE$60,579
- Korlym$51,106
- Wegovy$40,163
- Kerendia$36,606
- MYALEPT$35,830
- Yorvipath$32,117
- FREESTYLE LIBRE 3$31,116
- Tresiba$20,782
- RYBELSUS$20,770
- NEXLIZET$15,793
- NEXLETOL$15,793
- Synthroid$12,814
- Xultophy 100/3.6$11,067
- STEGLATRO$10,059
- RECORLEV$7,429
- INVOKANA$7,230
How this compares
$775,288 in reported general payments places this provider in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
See all endocrinology, diabetes & metabolism providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KorlymMifepristone | 44 | $1,802,782 |
| JardianceEmpagliflozin | 669 | $868,156 |
| OzempicSemaglutide | 590 | $851,904 |
| TrulicityDulaglutide | 308 | $439,947 |
| FarxigaDapagliflozin Propanediol | 300 | $315,700 |
| MounjaroTirzepatide | 211 | $287,107 |
| Tresiba Flextouch U-200Insulin Degludec | 140 | $250,746 |
| RybelsusSemaglutide | 107 | $225,923 |
| KerendiaFinerenone | 120 | $173,856 |
| Humulin R U-500 KwikpenInsulin Regular, Human | 89 | $164,075 |
| Tresiba Flextouch U-100Insulin Degludec | 130 | $86,684 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 315 | $56,341 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 95 | $55,866 |
| Humalog Kwikpen U-200Insulin Lispro | 42 | $55,218 |
| Humalog Kwikpen U-100Insulin Lispro | 182 | $52,014 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Corcept TherapeuticsKorlym | $52,622 | $1,802,78244 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $248,534 | $1,092,877745 claims |
| Boehringer IngelheimJardiance, Tradjenta | $27,666 | $894,524694 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Humalog | $214,360 | $736,484558 claims |
| AstraZenecaFarxiga | $1,689 | $315,700300 claims |
| BayerKerendia | $37,334 | $173,856120 claims |
| AmgenProlia | $1,732 | $31,06218 claims |
| MerckJanuvia | $10,803 | $25,20616 claims |
| Esperion Therapeutics, Inc.Nexlizet | $16,603 | $17,91224 claims |
| AbbVieSynthroid | $13,111 | $14,072164 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $105 | $8,626796 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 360 endocrinology, diabetes & metabolism providers in Massachusetts.
Other endocrinology, diabetes & metabolism in Fall River
- Kishore LakshmanFall River$9K
- Jason GagliaBoston$2.4M
- Vanita ArodaBoston$482K
- Michael RosenblattBoston$447K
- Steven RussellBoston$445K
- Nitin TrivediWorcester$403K
- Beverly BillerBoston$346K
- Christos MantzorosBoston$243K
- Peter ButlerFlorence$216K
- Augusto Caballero-RoblesBoston$150K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.